Drug Approval | April 29, 2026
AbbVie seeks FDA nod for RINVOQ use in severe alopecia areata
After Phase 3 results show major hair regrowth gains
After Phase 3 results show major hair regrowth gains
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Three-day programme focuses on advanced socket design, myoelectric technology and clinical skill development
Stakeholders call for coordinated action on diagnostics, vaccines, and health system readiness as the monsoon season approaches
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
Subscribe To Our Newsletter & Stay Updated
